# Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.

Study · id `cardio:ct-nct04564742` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04564742](<https://clinicaltrials.gov/study/NCT04564742>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04564742

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Heart failure; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4017 participants.

## Technical summary

Registry record NCT04564742. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-22 (actual); primary completion 2023-07-05 (actual). Results posted on 2025-03-07.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 4017 participants (enrolled count; ClinicalTrials.gov record NCT04564742, source copy `cardio:ctgov-nct04564742-2025-03-07`, retrieved 2026-10-26)
- Started: 2020-12-22 (actual) (ClinicalTrials.gov record NCT04564742, source copy `cardio:ctgov-nct04564742-2025-03-07`, retrieved 2026-10-26)
- Primary completion: 2023-07-05 (actual) (ClinicalTrials.gov record NCT04564742, source copy `cardio:ctgov-nct04564742-2025-03-07`, retrieved 2026-10-26)
- Completion: 2023-07-05 (actual) (ClinicalTrials.gov record NCT04564742, source copy `cardio:ctgov-nct04564742-2025-03-07`, retrieved 2026-10-26)
- Results first posted: 2025-03-07 (ClinicalTrials.gov record NCT04564742, source copy `cardio:ctgov-nct04564742-2025-03-07`, retrieved 2026-10-26)
- Countries: Sweden; United Kingdom (ClinicalTrials.gov record NCT04564742, source copy `cardio:ctgov-nct04564742-2025-03-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04564742-2025-03-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
- Acronym: DAPA-MI
- Condition: Acute Myocardial Infarction
- Condition: Heart Failure
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY
- Collaborator: Uppsala University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: Uppsala University (`cardio:org-uppsala-university`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure (`cardio:pubmed-38320489`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 41a5ba6a54f4375210d4e8455f673a486438906eed8bfe770e0f1ab83fa81bbc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
